Identification, genetic testing, and management of hereditary melanoma

Sancy Leachman, Olivia M. Lucero, Jone E. Sampson, Pamela Cassidy, William Bruno, Paola Queirolo, Paola Ghiorzo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Several distinct melanoma syndromes have been defined, and genetic tests are available for the associated causative genes. Guidelines for melanoma genetic testing have been published as an informal “rule of twos and threes,” but these guidelines apply to CDKN2A testing and are not intended for the more recently described non-CDKN2A melanoma syndromes. In order to develop an approach for the full spectrum of hereditary melanoma patients, we have separated melanoma syndromes into two types: “melanoma dominant” and “melanoma subordinate.” Syndromes in which melanoma is a predominant cancer type are considered melanoma dominant, although other cancers, such as mesothelioma or pancreatic cancers, may also be observed. These syndromes are associated with defects in CDKN2A, CDK4, BAP1, MITF, and POT1. Melanoma-subordinate syndromes have an increased but lower risk of melanoma than that of other cancer(s) seen in the syndrome, such as breast and ovarian cancer or Cowden syndrome. Many of these melanoma-subordinate syndromes are associated with well-established predisposition genes (e.g., BRCA1/2, PTEN). It is likely that these predisposition genes are responsible for the increased susceptibility to melanoma as well but with lower penetrance than that observed for the dominant cancer(s) in those syndromes. In this review, we describe our extension of the “rule of twos and threes” for melanoma genetic testing. This algorithm incorporates an understanding of the spectrum of cancers and genes seen in association with melanoma to create a more comprehensive and tailored approach to genetic testing.

Original languageEnglish (US)
Pages (from-to)77-90
Number of pages14
JournalCancer and Metastasis Reviews
Volume36
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Genetic Testing
Melanoma
Neoplasms
Multiple Hamartoma Syndrome
Guidelines
BRCA1 Gene
Penetrance
Neoplasm Genes
Mesothelioma
Pancreatic Neoplasms
Ovarian Neoplasms
Genes

Keywords

  • Gene panel sequencing
  • Genetic syndromes
  • Genetic testing
  • Inherited cancer risk
  • Melanoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Identification, genetic testing, and management of hereditary melanoma. / Leachman, Sancy; Lucero, Olivia M.; Sampson, Jone E.; Cassidy, Pamela; Bruno, William; Queirolo, Paola; Ghiorzo, Paola.

In: Cancer and Metastasis Reviews, Vol. 36, No. 1, 01.03.2017, p. 77-90.

Research output: Contribution to journalArticle

Leachman, Sancy ; Lucero, Olivia M. ; Sampson, Jone E. ; Cassidy, Pamela ; Bruno, William ; Queirolo, Paola ; Ghiorzo, Paola. / Identification, genetic testing, and management of hereditary melanoma. In: Cancer and Metastasis Reviews. 2017 ; Vol. 36, No. 1. pp. 77-90.
@article{3e63f569229b456abb5f696a3080947a,
title = "Identification, genetic testing, and management of hereditary melanoma",
abstract = "Several distinct melanoma syndromes have been defined, and genetic tests are available for the associated causative genes. Guidelines for melanoma genetic testing have been published as an informal “rule of twos and threes,” but these guidelines apply to CDKN2A testing and are not intended for the more recently described non-CDKN2A melanoma syndromes. In order to develop an approach for the full spectrum of hereditary melanoma patients, we have separated melanoma syndromes into two types: “melanoma dominant” and “melanoma subordinate.” Syndromes in which melanoma is a predominant cancer type are considered melanoma dominant, although other cancers, such as mesothelioma or pancreatic cancers, may also be observed. These syndromes are associated with defects in CDKN2A, CDK4, BAP1, MITF, and POT1. Melanoma-subordinate syndromes have an increased but lower risk of melanoma than that of other cancer(s) seen in the syndrome, such as breast and ovarian cancer or Cowden syndrome. Many of these melanoma-subordinate syndromes are associated with well-established predisposition genes (e.g., BRCA1/2, PTEN). It is likely that these predisposition genes are responsible for the increased susceptibility to melanoma as well but with lower penetrance than that observed for the dominant cancer(s) in those syndromes. In this review, we describe our extension of the “rule of twos and threes” for melanoma genetic testing. This algorithm incorporates an understanding of the spectrum of cancers and genes seen in association with melanoma to create a more comprehensive and tailored approach to genetic testing.",
keywords = "Gene panel sequencing, Genetic syndromes, Genetic testing, Inherited cancer risk, Melanoma",
author = "Sancy Leachman and Lucero, {Olivia M.} and Sampson, {Jone E.} and Pamela Cassidy and William Bruno and Paola Queirolo and Paola Ghiorzo",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s10555-017-9661-5",
language = "English (US)",
volume = "36",
pages = "77--90",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Identification, genetic testing, and management of hereditary melanoma

AU - Leachman, Sancy

AU - Lucero, Olivia M.

AU - Sampson, Jone E.

AU - Cassidy, Pamela

AU - Bruno, William

AU - Queirolo, Paola

AU - Ghiorzo, Paola

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Several distinct melanoma syndromes have been defined, and genetic tests are available for the associated causative genes. Guidelines for melanoma genetic testing have been published as an informal “rule of twos and threes,” but these guidelines apply to CDKN2A testing and are not intended for the more recently described non-CDKN2A melanoma syndromes. In order to develop an approach for the full spectrum of hereditary melanoma patients, we have separated melanoma syndromes into two types: “melanoma dominant” and “melanoma subordinate.” Syndromes in which melanoma is a predominant cancer type are considered melanoma dominant, although other cancers, such as mesothelioma or pancreatic cancers, may also be observed. These syndromes are associated with defects in CDKN2A, CDK4, BAP1, MITF, and POT1. Melanoma-subordinate syndromes have an increased but lower risk of melanoma than that of other cancer(s) seen in the syndrome, such as breast and ovarian cancer or Cowden syndrome. Many of these melanoma-subordinate syndromes are associated with well-established predisposition genes (e.g., BRCA1/2, PTEN). It is likely that these predisposition genes are responsible for the increased susceptibility to melanoma as well but with lower penetrance than that observed for the dominant cancer(s) in those syndromes. In this review, we describe our extension of the “rule of twos and threes” for melanoma genetic testing. This algorithm incorporates an understanding of the spectrum of cancers and genes seen in association with melanoma to create a more comprehensive and tailored approach to genetic testing.

AB - Several distinct melanoma syndromes have been defined, and genetic tests are available for the associated causative genes. Guidelines for melanoma genetic testing have been published as an informal “rule of twos and threes,” but these guidelines apply to CDKN2A testing and are not intended for the more recently described non-CDKN2A melanoma syndromes. In order to develop an approach for the full spectrum of hereditary melanoma patients, we have separated melanoma syndromes into two types: “melanoma dominant” and “melanoma subordinate.” Syndromes in which melanoma is a predominant cancer type are considered melanoma dominant, although other cancers, such as mesothelioma or pancreatic cancers, may also be observed. These syndromes are associated with defects in CDKN2A, CDK4, BAP1, MITF, and POT1. Melanoma-subordinate syndromes have an increased but lower risk of melanoma than that of other cancer(s) seen in the syndrome, such as breast and ovarian cancer or Cowden syndrome. Many of these melanoma-subordinate syndromes are associated with well-established predisposition genes (e.g., BRCA1/2, PTEN). It is likely that these predisposition genes are responsible for the increased susceptibility to melanoma as well but with lower penetrance than that observed for the dominant cancer(s) in those syndromes. In this review, we describe our extension of the “rule of twos and threes” for melanoma genetic testing. This algorithm incorporates an understanding of the spectrum of cancers and genes seen in association with melanoma to create a more comprehensive and tailored approach to genetic testing.

KW - Gene panel sequencing

KW - Genetic syndromes

KW - Genetic testing

KW - Inherited cancer risk

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=85014770636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014770636&partnerID=8YFLogxK

U2 - 10.1007/s10555-017-9661-5

DO - 10.1007/s10555-017-9661-5

M3 - Article

VL - 36

SP - 77

EP - 90

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 1

ER -